Defining direct targets of transcription factors and regulatory pathways is key to understanding their roles in physiology and disease. We combined SLAM-seq [thiol(SH)-linked alkylation for the metabolic sequencing of RNA], a method for direct quantification of newly synthesized messenger RNAs (mRNAs), with pharmacological and chemical-genetic perturbation in order to define regulatory functions of two transcriptional hubs in cancer, BRD4 and MYC, and to interrogate direct responses to BET bromodomain inhibitors (BETis). We found that BRD4 acts as general coactivator of RNA polymerase II-dependent transcription, which is broadly repressed upon high-dose BETi treatment. At doses triggering selective effects in leukemia, BETis deregulate a small set of hypersensitive targets including MYC. In contrast to BRD4, MYC primarily acts as a selective transcriptional activator controlling metabolic processes such as ribosome biogenesis and de novo purine synthesis. Our study establishes a simple and scalable strategy to identify direct transcriptional targets of any gene or pathway.
T ranscription factors (TFs) and chromatin regulators govern the identity and fate of a cell, and their mutation or dysregulation drives cancer and other human diseases (1) . Epigenetic regulators that maintain aberrant cell states have emerged as accessible entry points for targeted therapies (2) . Among these, BET bromodomain inhibitors (BETis) have shown activity in preclinical models of leukemia and other cancers (2, 3) , yet underlying mechanisms remain poorly understood. Although BETis interfere with multiple BET proteins, therapeutic effects have mainly been attributed to displacement of BRD4 from acetylated histones and repression of its target genes. In hematopoietic malignancies, BETis commonly trigger repression of MYC (4-6), an oncogenic TF that is overexpressed in up to 70% of human cancers (7) .
Defining direct targets of transcriptional regulators such as BRD4 and MYC is critical, both for understanding their cellular function and for therapy development. However, deciphering direct regulatory relationships remains challenging because genomic binding of a factor does not predict regulatory functions on neighboring genes, whereas conventional expression analyses after gene perturbation preclude a clear distinction between direct and indirect effects owing to vast differences in mRNA and protein half-lives (fig. S1A) (8, 9 ). An ideal strategy for defining direct transcriptional targets would combine rapid protein perturbation and subsequent measurement of changes in mRNA output at time scales that preclude secondary effects.
Thiol(SH)-linked alkylation for the metabolic sequencing of RNA (SLAM-seq) enables the direct quantification of 4-thiouridine (4sU)-labeled mRNAs within the total mRNA pool (10) . This is achieved through alkylation of the thiol group in 4sU (fig. S1B), which prompts misincorporation of G during reverse transcription, enabling the detection of 4sU as thymine-to-cytosine (T>C) conversion in 3′-end mRNA-sequencing. To test the suitability of SLAM-seq for detecting immediate and global changes in mRNA production, we measured responses to inhibition of CDK9, a cyclin-dependent kinase globally required for releasing RNA polymerase II (Pol2) from promoterproximal pausing (11) . To this end, we treated human K562 leukemia cells with the CDK inhibitor flavopiridol and performed SLAM-seq after 45 min of 4sU labeling ( fig. S1C ). As expected, only a few transcripts showed deregulation at the total mRNA level, whereas transcripts containing T>C conversions were broadly repressed (fig. S1, D and E). We further optimized the setup to eliminate noise introduced by polymerase chain reaction and sequencing errors ( fig. S1F ) and to maximize the recovery of labeled reads ( fig. S1G ). To test whether SLAM-seq captures more specific transcriptional responses, we treated K562 cells with small-molecule inhibitors of their driving oncogene BCR-ABL, as well as the kinases Mek and Akt, which act in distinct signaling cascades downstream of BCR-ABL ( fig. S2A) (12) . SLAM-seq revealed prominent immediate responses to these inhibitors ( fig. S2 , B and C) that were not biased by mRNA half-lives ( fig. S2D ). Combined inhibition of Mek and Akt approximated to effects of BCR-ABL inhibition, recapitulating their function as key effector pathways of BCR-ABL ( fig. S2 , E and F). Together, these pilot studies establish SLAM-seq as a rapid and scalable approach for probing direct transcriptional responses to drug treatment.
To generalize this approach for investigating the vast number of regulators for which, as in the case of BRD4, no selective inhibitors are available, we sought to combine SLAM-seq with chemicalgenetic protein degradation (Fig. 1A) . To achieve sufficiently rapid kinetics, we used the auxininducible degron (AID) system reported to degrade AID-tagged proteins within less than 1 hour (13) . Specifically, we introduced a minimal AIDtag into the BRD4 locus of K562 cells (Fig. 1B) and transduced homozygous knock-in clones with a lentiviral vector expressing the rice F-box protein transport inhibitor response 1 (Tir1), which mediates ubiquitination of AID-tagged proteins upon treatment with IAA (indole-3-acetic acid). IAA treatment of edited cells triggered a highly specific and near-complete degradation of BRD4 within 30 min ( Fig. 1B; fig. S3 , A to C; and table S1). Whereas introduction of the tag or Tir1 expression and IAA treatment were well tolerated, prolonged BRD4 degradation strongly suppressed cell proliferation ( fig. S3 , D and E) in line with its essential function (14) .
SLAM-seq after acute BRD4 degradation and 60 min of 4sU labeling revealed a global downregulation of transcription ( Fig. 1C and fig. S3F ), similar to effects of CDK9 inhibition. These effects are not due to displacement of core transcriptional machinery because loss of BRD4 did not impair chromatin binding of factors involved in transcriptional initiation (TBP1 and MED1) or pause-release and elongation (CDK9, Cyclin T1, and SPT5) (Fig. 1D) . Whereas initiationassociated phosphorylation of Pol2 at serine 5 (S5) of its C-terminal repeat domain was unaffected, BRD4 degradation led to a marked reduction of elongation-associated serine 2 (S2)-phosphorylated Pol2, indicating a defect in promoter proximal pause release. Spike-in controlled chromatin immunoprecipitation (ChIP)-sequencing upon BRD4 degradation showed an accumulation of total and S5-phosphorylated Pol2 levels at active transcription start sites (TSSs), whereas total, S5-, and S2-phophorylated Pol2 were reduced throughout gene bodies (Fig. 1, E and F, and fig. S4 ). These results are in line with a recent report showing a widespread reduction of transcription upon pan-BET protein degradation independent of CDK9 recruitment (15) and convincingly show that BRD4 globally controls transcription by promoting the release of stalled Pol2.
Although these findings are consistent with the promiscuous binding of BRD4 to active TSS (16), they contrast with selective effects of BETis, which have been widely reported based on results of conventional expression analyses. To define immediate transcriptional responses to BETis, we performed SLAM-seq after treatment with different doses of the BETi JQ1 (17) in K562 and human MV4-11 acute myeloid leukemia (AML) cells. In both cell types, high-dose JQ1 treatment (1 or 5 mM) broadly suppressed transcription ( Fig. 2A and fig. S5A ) and globally reduced Pol2-S2 phosphorylation ( fig. S5B ) similar to effects observed after BRD4 degradation, showing that global transcriptional functions of BRD4 are BET bromodomain-dependent. Effects of high-dose BETis on Pol2-S2 phosphorylation were recapitulated after knockdown of BRD4 but not BRD2 or BRD3 (fig. S5, C and D), indicating that global effects of BETis are primarily mediated by BRD4 inhibition and cannot be compensated by other BET proteins.
Because JQ1 doses above 1 mM vastly exceed growth-inhibitory concentrations in AML and other sensitive cell lines, we explored direct transcriptional responses to a more selective dose of 200 nM, which triggers strong antileukemic effects in a wide range of AML models (4) . In K562 cells, one of few BETi-insensitive leukemia cell lines, 200 nM JQ1 induced a selective deregulation of a small number of transcripts (Fig. 2B) . Treatment of two highly sensitive AML cell lines with the same dose triggered transcriptional responses that were comparable in scale ( 14) . These findings are in line with the notion that sensitivity to BETis at the cellular level is determined by secondary adaptation rather than differences in the primary transcriptional response (18, 19) . We also noted a small set of genes that were commonly up-regulated after BET inhibition or BRD4 degradation ( fig. S6E ) through mechanisms that remain elusive. Collectively, our results reveal a profound dose-dependency of direct responses to BETis and show that therapeutically active doses trigger antileukemic effects by deregulating a small set of hypersensitive genes.
We next explored whether the BETi hypersensitivity of certain transcripts simply reflects a pronounced sensitivity to interference with general Pol2 pause-release machinery. To test this, we used SLAM-seq to compare transcriptional responses to BET inhibition (200 nM JQ1) to effects triggered by different doses of the selective CDK9 inhibitor NVP-2 (20) . Whereas high-dose CDK9 inhibition (60 nM NVP-2) globally suppressed transcription, an intermediate dose (6 nM NVP-2) triggered selective transcriptional responses that were distinct from the conserved response to BETis (Fig. 2, D and E, and fig. S7, A  and B) . Because CDK9 and BET inhibitors display strong synergistic effects ( fig. S7, C and D (Fig. 2,  D and E, and fig. S7A ). These observations hold true in a genetically distinct AML cell line ( fig. S7 , E and F), suggesting that the therapeutic synergy between BETis and CDK9i is largely based on synergistic suppression of global transcription, raising concerns about toxicities of this combination. These results also suggest that therapeutically active doses of CDK9 and BET inhibitors exploit different bottlenecks in Pol2 pause-release to trigger selective transcriptional responses.
To investigate whether BETi hypersensitivity is determined by specific chromatin features at target genes, we first tested whether BRD4 profiles. Both the H3K27ac-based regulatory potential of genes as well as their association with superenhancers (22) predicted hypersensitivity to BETis with modest accuracy (AUC 0.66 and 0.64, respectively) ( fig. S8B ). However, two-thirds of BETi-sensitive genes could not be assigned to superenhancers, and the vast majority of expressed superenhancer-associated genes did not respond to BETi treatment (Fig. 2, F and G) . These observations hold true in other leukemia cell lines ( fig. S8D ) and show that the sensitivity to BET inhibition is associated with, but not determined by, the presence of superenhancers, suggesting that more complex factors underlie this phenomenon.
To further explore determinants of BETi hypersensitivity, we took advantage of extensive profiling data available for K562 cells (23, 24) and devised an unbiased approach for modeling combinatorial modes of gene regulation. Specifically, we extracted signals of 214 ChIP-and methylome-sequencing experiments within 500 and 2000 base pairs (bp) around the TSS of BETisensitive and -unresponsive genes and used this data to train various classification models that were later evaluated based on held-out test genes ( Fig. 2H and fig. S8E ). This approach yielded multiple classifiers that predicted BETi sensitivity with high fidelity (AUC > 0.8) (Fig. 2I and  fig. S8F ), among them a generalized linear model (GLM) derived through elastic net regression. Reanalyzing coefficients of this model revealed that several factors, including high levels of TSSproximal REST and H3K27ac, are associated with BETi hypersensitivity, whereas high occupancy of SUPT5H (SPT5), itself a regulator of elongation (25, 26) , was the strongest negative predictor (Fig. 2J and fig. S9A ). Unsupervised clustering revealed that predictive TFs and cofactors are enriched only at distinct subclusters of BETisensitive or -unresponsive genes (Fig. 2J and fig.  S9B ), suggesting that the transcriptional response to BETis is determined by locus-specific regulators and cannot be predicted on the basis of a single unifying chromatin factor.
Therapeutic effects of BETis are likely mediated through deregulation of multiple hypersensitive genes. Although repression of MYC has been identified as a common and relevant effector mechanism in leukemia (4), direct regulatory functions of MYC remain under debate. Previous reports have described activating or repressive effects of MYC on specific target genes, whereas other studies suggest that MYC acts as a general transcriptional amplifier (27) (28) (29) (30) (31) . To test these models, we sought to measure direct changes in mRNA output after acute loss of endogenous MYC. We therefore engineered an AID-tag into the endogenous MYC locus of K562 cells (Fig. 3A and fig. S10 ), which in homozygous Tir1-expressing clones allowed for rapid degradation of MYC within less than 30 min (Fig. 3B) . We then used SLAM-seq to quantify the output of newly synthesized mRNAs over 60 min after MYC degradation. In contrast to degradation of BRD4, acute loss of MYC resulted in highly specific rather than global changes in mRNA production (Fig. 3C ). These were dominated by repressive effects on 712 genes, whereas only 15 mRNAs were strongly up-regulated ( fig. S11A) . Hence, in K562 cells, MYC does not act as a direct repressor or general amplifier of transcription but predominantly functions as a transcriptional activator of specific target genes.
Because MYC is known to occupy most active promoters (27) , we next investigated how MYC exerts selective transcriptional activation despite ubiquitous binding. To this end, we trained classification models to predict MYC-dependent transcripts (FDR ≤ 0.1, log 2 FC ≤ -1) based on different ChIP-seq signals at their promoter. Elastic net regression yielded a simple GLM that was highly predictive of MYC-dependent gene regulation (AUC 0.91) (fig. S11B ). The strongest contributor in this model was the abundance of MYC itself ( fig. S11C ). Although the presence of MYC at promoters determined by conventional peak calling fails to identify MYC-sensitive transcripts, binding levels of MYC or its cofactor MAX predict MYC-dependent gene regulation with intermediate accuracy (AUC 0.76 and 0.74, respectively) (fig. S11, D and E). These results suggest that genes directly activated by MYC are defined by strong binding of MYC and by further modulation through additional factors such as MNT, NKRF, TBL1XR1, EP300, and YY1.
To investigate the cellular function of MYCdependent gene regulation, we performed gene ontology analysis of direct MYC target genes in K562 cells. Acute MYC degradation predominantly led to down-regulation of genes associated with protein and nucleotide biosynthesis, including 36% of all ribosome biogenesis factors, key regulators in adenosine 5′-monophosphate (AMP) metabolism, and all six enzymes of the de novo purine synthesis pathway (Fig. 3, C and D, and table S2). MYC degradation progressively impaired protein synthesis (Fig. 3E ) and led to a strong reduction in cellular AMP and guanosine 5′-monophosphate (GMP) levels as well as their upstream intermediate aminoimidazole carboxamide ribonucleotide (AICAR) before the onset of cell proliferation defects ( Fig. 3F and fig. S12 , A and B). MYC's role as a direct regulator of key enzymes in protein and nucleotide biosynthesisas well as several subunits of RNA polymerases I, II, and III ( fig. S12C )-provide an explanation for the reported increase in total cellular RNA upon MYC overexpression and support the notion that these effects are secondary rather than due to global transcriptional effects (32) .
To test whether direct transcriptional functions of MYC are conserved in other cellular contexts, we introduced homozygous AID-tags into the MYC locus of HCT116 human colon carcinoma cells. As with K562 cells, IAA treatment of TIR1-expressing HCT116
MYC-AID cells triggered complete degradation of MYC within less than 30 min (Fig. 3G) . SLAM-seq profiling revealed a selective transcriptional response (Fig. 3H and  fig. S12D ) that affected the same cellular processes ( fig. S12E ) and correlated with effects observed in K562 cells [Pearson correlation coefficient (R) = 0.64] (Fig. 3H) . To test whether the conservation of MYC targets extends to other cancer types, we derived a signature of the 100 most strongly down-regulated genes in SLAMseq (table S3) and compared its expression with MYC levels in a panel of 672 cancer cell lines (33) . Expression of MYC and our MYC target signature correlated well (Fig. 3I) , except for a small fraction of outliers. All of these express high levels of MYCN or MYCL ( fig. S13A ), indicating that MYC paralogs have redundant functions in the regulation of core MYC targets. Our signature of direct MYC targets was also strongly correlated with MYC levels in publicly available RNA-seq profiles from 5583 primary patient samples across 11 major human cancers (Fig. 3J and  fig. S13B ) (34) . Together, these findings suggest that MYC drives expression of a conserved set of transcriptional targets, which should be considered as entry points for blocking its oncogenic functions.
In summary, combining rapid chemical-genetic perturbation and SLAM-seq establishes a simple yet powerful strategy for probing specific and global direct functions of TFs and cofactors. Using this approach, we functionally characterize BRD4, a protein widely studied as a regulator of lineageand disease-associated expression programs, as a general cofactor in transcriptional pause-release. We also found that MYC, which has previously been implicated as a global transcriptional amplifier, activates a confined and conserved set of target genes to fuel basic anabolic processes, particularly protein and nucleotide biosynthesis. More generally, by enabling the direct quantification of changes in mRNA output, SLAM-seq provides a simple, robust, and scalable method for defining direct transcriptional responses to any perturbation and thereby exploring the regulatory wiring of a cell.
